A Novel Device for Gestational Diabetes Control

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-45
SponsorRambam Health Care Campus

About this trial

Rationale of the study: Gestational diabetes mellitus (GDM) is very common and the rate of women suffering from it expected to increase in the next years. It is associated with maternal and fetal morbidity and the risk is correlated to the patient's degree of glucose control which can be achieved through a change in lifestyle or medication. Several studies have demonstrated the effectiveness of mobile apps in improving obstetric outcomes in GDM. In addition, the LUMEN device is a breathing device that produces dietary and exercise recommendations based on CO2 levels and improves metabolic parameters in patients with type 2 diabetes. No work has been done on its effectiveness in treating GDM. Aims of the study: Comparison of metabolic outcomes in women with gestational diabetes, with or without the use of LUMEN app. Design: This will be an open label parallel group 1:1 randomized-controlled trial Methods: the investigators will recruit women diagnosed with GDM. The women will be randomized to the intervention arm that will use the LUMEN device and app or to the control arm that will use a free mobile tracking app. The women will be required to monitor their blood sugar levels daily and to have GDM follow-up in the feto-maternal outpatient clinic, as is customary in GDM. After the birth, the maternal and neonatal outcome will be recorded. Based on past research data, a recruitment of 170 is needed to demonstrate a 16.7% decrease in insulin use to balance diabetes, with α = 0.05 and β = 80.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Gravidas aged 18-45 years

Singleton pregnancy

Diagnosed with GDM in current pregnancy

First visit to high-risk pregnancy clinic is no late than 32 weeks' gestation

Disqualifiers

Insulin and medications for glycemic control

Antipsychotics

Diuretics

Corticosteroids

Trial design

Design model

Parallel

Treatments tested in this trial

  • Lumen

    Device

    subjects will use the Lumen device and mobile phone application, which will guide them once a day after the night fast regarding their daily diet, sleep, and routines according to their Lumen measurements. Subjects will need Google Fit (Android) or Apple Health Kit (iOS) and will be encouraged to communicate with a study investigator via the app during the entirety of the study to resolve technical questions about the device and data collection.

  • Glucose monitoring mobile app

    Other intervention

    The control group will use a designated glucose monitoring mobile app to record their glucose levels

Treatment groups

120 Participants
are divided into 2 treatment groups
Group A: The Lumen groupExperimental treatment 1 intervention
Group B: The control groupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

To evaluate the average change in blood glucose levels with the use the Lumen device

The blood glucose levels will be recorded and the average levels will be compared between the groups

Time frame
From date of randomization until the date delivery, assessed up to 4 months

Secondary outcomes

1

to compare the maternal age

maternal age in years

Time frame
From date of randomization until the date delivery, assessed up to 4 months
2

to compare the gestational age at delivery

gestational age at delivery in weeks

Time frame
From date of randomization until the date delivery, assessed up to 4 months
3

to compare the parity between the groups

parity

Time frame
From date of randomization until the date delivery, assessed up to 4 months
4

to compare the rate of family history of DM

family history of DM

Time frame
From date of randomization until the date delivery, assessed up to 4 months

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: